Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1729 to 1733 of 1733 entries
Sorted by: Best Match Show Resources per page
Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adults.

Journal of the neurological sciences

Abboud H, Briggs F, Buerki R, Elkasaby M, BacaVaca GF, Fotedar N, Geiger C, Griggins C, Lee C, Lewis A, Serra A, Shrestha R, Winegardner J, Shaikh A.
PMID: 34998237
J Neurol Sci. 2021 Dec 31;434:120124. doi: 10.1016/j.jns.2021.120124. Epub 2021 Dec 31.

BACKGROUND AND OBJECTIVES: To evaluate residual symptoms after all-cause autoimmune encephalitis in a real-life outpatient setting and compare long-term outcome measures. A secondary objective was to identify correlates of poor outcomes.METHODS: We analyzed patients referred to the Neuroimmunology clinic...

Cite
Abboud H, Briggs F, Buerki R, et al. Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adults. J Neurol Sci. 2021;434:120124doi: 10.1016/j.jns.2021.120124.
Abboud, H., Briggs, F., Buerki, R., Elkasaby, M., BacaVaca, G. F., Fotedar, N., Geiger, C., Griggins, C., Lee, C., Lewis, A., Serra, A., Shrestha, R., Winegardner, J., & Shaikh, A. (2021). Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adults. Journal of the neurological sciences, 434120124. https://doi.org/10.1016/j.jns.2021.120124
Abboud, Hesham, et al. "Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adults." Journal of the neurological sciences vol. 434 (2021): 120124. doi: https://doi.org/10.1016/j.jns.2021.120124
Abboud H, Briggs F, Buerki R, Elkasaby M, BacaVaca GF, Fotedar N, Geiger C, Griggins C, Lee C, Lewis A, Serra A, Shrestha R, Winegardner J, Shaikh A. Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adults. J Neurol Sci. 2021 Dec 31;434:120124. doi: 10.1016/j.jns.2021.120124. Epub 2021 Dec 31. PMID: 34998237.
Copy Download .nbib Format: NLM
The nuclear transcription factor, TAF7, is a cytoplasmic regulator of protein synthesis.

Science advances

Cheng D, Semmens K, McManus E, Chen Q, Meerzaman D, Wang X, Hafner M, Lewis BA, Takahashi H, Devaiah BN, Gegonne A, Singer DS.
PMID: 34890234
Sci Adv. 2021 Dec 10;7(50):eabi5751. doi: 10.1126/sciadv.abi5751. Epub 2021 Dec 10.

[Figure: see text].

Cite
Cheng D, Semmens K, McManus E, et al. The nuclear transcription factor, TAF7, is a cytoplasmic regulator of protein synthesis. Sci Adv. 2021;7(50):eabi5751doi: 10.1126/sciadv.abi5751.
Cheng, D., Semmens, K., McManus, E., Chen, Q., Meerzaman, D., Wang, X., Hafner, M., Lewis, B. A., Takahashi, H., Devaiah, B. N., Gegonne, A., & Singer, D. S. (2021). The nuclear transcription factor, TAF7, is a cytoplasmic regulator of protein synthesis. Science advances, 7(50), eabi5751. https://doi.org/10.1126/sciadv.abi5751
Cheng, Dan, et al. "The nuclear transcription factor, TAF7, is a cytoplasmic regulator of protein synthesis." Science advances vol. 7,50 (2021): eabi5751. doi: https://doi.org/10.1126/sciadv.abi5751
Cheng D, Semmens K, McManus E, Chen Q, Meerzaman D, Wang X, Hafner M, Lewis BA, Takahashi H, Devaiah BN, Gegonne A, Singer DS. The nuclear transcription factor, TAF7, is a cytoplasmic regulator of protein synthesis. Sci Adv. 2021 Dec 10;7(50):eabi5751. doi: 10.1126/sciadv.abi5751. Epub 2021 Dec 10. PMID: 34890234.
Copy Download .nbib Format: NLM
Editors' Note: Automated Quantitative Pupillometry in the Critically Ill: A Systematic Review of the Literature.

Neurology

Lewis A, Galetta S.
PMID: 34903615
Neurology. 2021 Dec 14;97(24):1138. doi: 10.1212/WNL.0000000000012979.

No abstract available.

Cite
Lewis A, Galetta S. Editors' Note: Automated Quantitative Pupillometry in the Critically Ill: A Systematic Review of the Literature. Neurology. 2021;97(24):1138doi: 10.1212/WNL.0000000000012979.
Lewis, A., & Galetta, S. (2021). Editors' Note: Automated Quantitative Pupillometry in the Critically Ill: A Systematic Review of the Literature. Neurology, 97(24), 1138. https://doi.org/10.1212/WNL.0000000000012979
Lewis, Ariane, and Galetta, Steven. "Editors' Note: Automated Quantitative Pupillometry in the Critically Ill: A Systematic Review of the Literature." Neurology vol. 97,24 (2021): 1138. doi: https://doi.org/10.1212/WNL.0000000000012979
Lewis A, Galetta S. Editors' Note: Automated Quantitative Pupillometry in the Critically Ill: A Systematic Review of the Literature. Neurology. 2021 Dec 14;97(24):1138. doi: 10.1212/WNL.0000000000012979. PMID: 34903615.
Copy Download .nbib Format: NLM
GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia.

Current neuropharmacology

Volk DW, Lewis DA.
PMID: 22545031
Curr Neuropharmacol. 2005 Jan;3(1):45-62. doi: 10.2174/1570159052773396.

Cognitive deficits, including impairments in working memory that have been linked to the prefrontal cortex, are among the most debilitating and difficult to treat features of schizophrenia. Consequently, the identification of potential targets informed by the pathophysiology of the...

Cite
Volk DW, Lewis DA. GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia. Curr Neuropharmacol. 2005;3(1):45-62doi: 10.2174/1570159052773396.
Volk, D. W., & Lewis, D. A. (2005). GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia. Current neuropharmacology, 3(1), 45-62. https://doi.org/10.2174/1570159052773396
Volk, David W, and Lewis, David A. "GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia." Current neuropharmacology vol. 3,1 (2005): 45-62. doi: https://doi.org/10.2174/1570159052773396
Volk DW, Lewis DA. GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia. Curr Neuropharmacol. 2005 Jan;3(1):45-62. doi: 10.2174/1570159052773396. PMID: 22545031; PMCID: PMC3338098.
Copy Download .nbib Format: NLM
Changing the Chairs: Impact of Workshop Activities in Assisting Chemistry Department Chairs in Achieving Racial and Ethnic Diversity.

Greene J, Lewis PA, Richmond GL, Stockard J.
UIID-AD: 1019
2011;88:721-725. doi: 10.1021/ed100526b.

To address the low levels of underrepresented minority (URM) faculty in top-ranked chemistry departments, the National Science Foundation, the U.S. Department of Energy, and the National Institutes of Health jointly sponsored a workshop for academic chemistry leaders in September...

Cite
Greene J, Lewis PA, Richmond GL, et al. Changing the Chairs: Impact of Workshop Activities in Assisting Chemistry Department Chairs in Achieving Racial and Ethnic Diversity. 2011;88:721-725doi: 10.1021/ed100526b.
Greene, J., Lewis, P. A., Richmond, G. L., & Stockard, J. (2011). Changing the Chairs: Impact of Workshop Activities in Assisting Chemistry Department Chairs in Achieving Racial and Ethnic Diversity. 88721-725. https://doi.org/10.1021/ed100526b
Greene, J, et al. "Changing the Chairs: Impact of Workshop Activities in Assisting Chemistry Department Chairs in Achieving Racial and Ethnic Diversity." vol. 88 (2011): 721-725. doi: https://doi.org/10.1021/ed100526b
Greene J, Lewis PA, Richmond GL, Stockard J. Changing the Chairs: Impact of Workshop Activities in Assisting Chemistry Department Chairs in Achieving Racial and Ethnic Diversity. 2011;88:721-725. doi: 10.1021/ed100526b. UIID-AD: 1019.
Copy Download .nbib Format: NLM
Showing 1729 to 1733 of 1733 entries